Skyhawk Therapeutics, Inc., Monday announced a strategic research collaboration with Merck to develop novel small molecules that modulate RNA expression in neurological disorders with high unmet medical need.
The partnership will leverage Skyhawk's proprietary SkySTAR platform to identify small molecule candidates against RNA targets designated by Merck.
Skyhawk will oversee discovery and preclinical development, while Merck will assume responsibility for later-stage development and commercialization.
The deal is valued at over $2 billion, with Skyhawk eligible for milestone payments and tiered royalties on future sales.
For comments and feedback contact: editorial@rttnews.com
Business News
June 19, 2026 16:46 ET Major central banks continued to dominate the economic news flow this week too, led by the Federal Reserve, as they announced their latest policy decisions. The Federal Reserve policy session was in focus as it was the first to be led by the new chief Kevin Warsh. In Europe, central banks of the U.K. and Switzerland announced their rate decisions. In Asia, the Bank of Japan drew attention for its policy moves, while data out of China threw some light on the state of the economy.